Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 5.07
ARDM's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ARDM: 5.07 )
ARDM' s 10-Year Cash to Debt Range
Min: 0.84   Max: No Debt
Current: 5.07

Equity to Asset 0.67
ARDM's Equity to Asset is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ARDM: 0.67 )
ARDM' s 10-Year Equity to Asset Range
Min: -0.16   Max: 0.91
Current: 0.67

-0.16
0.91
F-Score: 5
Z-Score: -6.60
M-Score: 2.43
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -204.92
ARDM's Operating margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ARDM: -204.92 )
ARDM' s 10-Year Operating margin (%) Range
Min: -9165.74   Max: -77.3
Current: -204.92

-9165.74
-77.3
Net-margin (%) -221.92
ARDM's Net-margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ARDM: -221.92 )
ARDM' s 10-Year Net-margin (%) Range
Min: -9007.17   Max: -76.7
Current: -221.92

-9007.17
-76.7
ROE (%) -64.02
ARDM's ROE (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ARDM: -64.02 )
ARDM' s 10-Year ROE (%) Range
Min: -1351.09   Max: -32.62
Current: -64.02

-1351.09
-32.62
ROA (%) -42.77
ARDM's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ARDM: -42.77 )
ARDM' s 10-Year ROA (%) Range
Min: -115.1   Max: -24.49
Current: -42.77

-115.1
-24.49
ROC (Joel Greenblatt) (%) -4978.00
ARDM's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ARDM: -4978.00 )
ARDM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4978   Max: -41.8
Current: -4978

-4978
-41.8
EBITDA Growth (%) -14.50
ARDM's EBITDA Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ARDM: -14.50 )
ARDM' s 10-Year EBITDA Growth (%) Range
Min: -61.5   Max: 10.9
Current: -14.5

-61.5
10.9
EPS Growth (%) 14.50
ARDM's EPS Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ARDM: 14.50 )
ARDM' s 10-Year EPS Growth (%) Range
Min: -56.3   Max: 19.8
Current: 14.5

-56.3
19.8
» ARDM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ARDM



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.67
ARDM's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ARDM: 3.67 )
ARDM' s 10-Year P/B Range
Min: 0.1   Max: 24.71
Current: 3.67

0.1
24.71
P/S 11.00
ARDM's P/S is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ARDM: 11.00 )
ARDM' s 10-Year P/S Range
Min: 0.57   Max: 20.5
Current: 11

0.57
20.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.40
ARDM's Price/Net Cash is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ARDM: 4.40 )
ARDM' s 10-Year Price/Net Cash Range
Min: 3.3   Max: 30.06
Current: 4.4

3.3
30.06
Price/Net Current Asset Value 4.40
ARDM's Price/Net Current Asset Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ARDM: 4.40 )
ARDM' s 10-Year Price/Net Current Asset Value Range
Min: 3.23   Max: 24.38
Current: 4.4

3.23
24.38
Price/Tangible Book 3.67
ARDM's Price/Tangible Book is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ARDM: 3.67 )
ARDM' s 10-Year Price/Tangible Book Range
Min: 1.22   Max: 7.45
Current: 3.67

1.22
7.45
Price/Median PS Value 4.40
ARDM's Price/Median PS Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ARDM: 4.40 )
ARDM' s 10-Year Price/Median PS Value Range
Min: 0.65   Max: 26.55
Current: 4.4

0.65
26.55
Forward Rate of Return (Yacktman) -110.23
ARDM's Forward Rate of Return (Yacktman) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ARDM: -110.23 )
ARDM' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 8.3   Max: 8.4
Current: -110.23

8.3
8.4

Business Description

Industry: »
Compare: » details
Aradigm Corporation, a California corporation was incorporated in 1991. It is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs delivered by inhalation for the treatment and prevention of severe respiratory diseases. It invested a large amount of capital to develop drug delivery technologies. The Company's development candidates include proprietary formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with the severe respiratory diseases such as non-cystic fibrosis bronchiectasis (BE) and cystic fibrosis (CF). Its proprietary programs under development include, Inhaled Ciprofloxacin and Smoking Cessation Therapy. Ciprofloxacin has been approved by the FDA as an anti-infective agent and is widely used for the acute treatment of a variety of bacterial infections, including exacerbations associated with pulmonary infections. ARD-1600 Inhaled Nicotine is used for Smoking Cessation Therapy. The Company is in a highly competitive industry. It is in the competition with pharmaceutical and biotechnology companies, hospitals, research organizations, individual scientists and nonprofit organizations engaged in the development of drugs and other therapies for the respiratory disease indications. It had 74 issued United States patents, with 14 additional United States patent applications pending. The research, development, testing, manufacturing, labeling, advertising, promotion, distribution, marketing and export, among other things, of any products it develops are subject to extensive regulation by governmental authorities in the United States and other countries.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide